Lyon Joseph Douglas sold $176K of CORT

Lyon Joseph Douglas (See Remarks) sold 1,540 shares of CORCEPT THERAPEUTICS INC (CORT) at $114.16 ($0.18M total) on 2026-08-03.

Original reporting
SEC EDGAR · Lyon Joseph Douglas
Published Aug 5, 2026, 9:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The only new information is the specific sale size, price, and post-transaction holdings; it does not provide new operational or financial guidance.

02

Market read

Traders may note the insider selling datapoint, but it is unlikely to drive a fundamental repricing without corroborating company-specific news.

03

What to watch

Check for additional Form 4s around the same period, whether the sale was part of broader planned selling, and compare sale size to typical insider activity.

Relevance 4/10Novelty 5/10Timing: filed after-hours on 2026-08-05, covering a sale dated 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reported by an officer.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics Form 4 shows officer Lyon Joseph Douglas sold 1,540 shares at $114.16 on 2026-08-03, totaling $175,806.40.

Expected impact

Likely limited near-term impact; treat as routine insider selling unless follow-on filings or unusual volume emerge.

Evidence & confidence

The filing is primary-source and time-stamped, but it does not include new company fundamentals, guidance, or regulatory/operational developments.

Market effects

No clear sector read-through from a single disclosed insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be tax- or diversification-driven and may not signal bearish fundamentals, especially without a stated 10b5-1 plan.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction disclosure.

  • Lyon Joseph Douglas

    Officer who sold 1,540 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.